Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?

Other authors

Institut Català de la Salut

[Dopazo C, Charco R] Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-08-30T10:11:42Z

2023-08-30T10:11:42Z

2023-03-29



Abstract

Perihilar cholangiocarcinoma; Liver transplantation; Outcomes


Colangiocarcinoma perihilar; Trasplantament hepàtic; Resultats


Colangiocarcinoma perihiliar; Trasplante hepático; Resultados


Perihilar cholangiocarcinoma (pCCA) is a challenging disease with limited options. Surgical resection and adjuvant therapy remain the only established treatment for those with resectable disease. Since the publication of the Mayo protocol in 2000, neoadjuvant chemoradiation and liver transplantation have become the standard of care in selected patients with unresectable de novo pCCA or resectable pCCA arising under primary sclerosing cholangitis. However, its application is diverse worldwide, and the need for donor organs is one of the main limitations. Also, differences in the neoadjuvant regimen used were observed. In this review, we discuss the latest results of this approach, the recommended tools for diagnostic work-up, and advances in systemic therapy to improve patient selection and long-term survival.

Document Type

Article


Published version

Language

English

Publisher

OAE Publishing

Related items

Hepatoma Research;9

http://dx.doi.org/10.20517/2394-5079.2022.75

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)